Illumina (ILMN) said Thursday it launched a whole-genome sequencing research workflow for molecular residual disease detection and opened early access to select clinical research partners.

The company said the workflow is expected to support residual disease detection and cancer genomic profiling using solid tumor and blood samples.

Illumina said the workflow can complete processing in about five days and targets analytical sensitivity down to 10 parts per million for certain tumors.

The company said its Dragen analysis software links tumor profiles with circulating tumor DNA data and achieved 99.5% analytical specificity in testing designed to distinguish tumor signals from background noise.

Illumina said it plans a broader commercial launch next year and is developing an additional workflow designed to support lower detection thresholds using NovaSeq X systems.

Price: 153.98, Change: +3.81, Percent Change: +2.54